Research Topics
| Peter GilbertSummaryAffiliation: Fred Hutchinson Cancer Research Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Endpoints in vaccine trialsMichael G Hudgens
Statistical Center for HIV Aids Research and Prevention, Program in Biostatistics, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Stat Methods Med Res 13:89-114. 2004....
Tests for comparing mark-specific hazards and cumulative incidence functionsPeter B Gilbert
Department of Biostatistics, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Lifetime Data Anal 10:5-28. 2004..This assessment helps guide development of anti-HIV therapies that surmount the problem of drug resistance...
On modeling HIV and T cells in vivo: assessing causal estimators in vaccine trialsW David Wick
Statistical Center for HIV and AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
PLoS Comput Biol 2:e64. 2006..In addition to uncovering a surprising immunological scenario, our results illustrate the utility of mechanistic modeling in biostatistics...
Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluationFusheng Li
Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Vaccine 24:6893-904. 2006..The usability of PTE peptide set was manifested by detection of Nef-specific CTL responses in HIV-1 subtype B infections...
Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi StudyIbou Thior
Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Mass 02115, USA
JAMA 296:794-805. 2006..These results demonstrate the risk of formula feeding to infants in sub-Saharan Africa, and the need for studies of alternative strategies. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00197587...
Simultaneous inferences on the contrast of two hazard functions with censored observationsPeter B Gilbert
Fred Hutchinson Cancer Research Center and Department of Biostatistics, University of Washington, Seattle, Washington 98109, USA
Biometrics 58:773-80. 2002..The simultaneous interval estimates are quite useful for identifying possible values of the contrast over time with a certain degree of confidence. The new proposals are illustrated with an example and a small simulation study...
The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacyPeter B Gilbert
Department of Biostatistics, University of Washington and Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109, USA
Biostatistics 9:263-76. 2008..The asymptotic properties of the procedures are established. In addition, the methods are studied in simulations and are applied to HIV genetic sequence data collected in the first HIV vaccine efficacy trial...
Evaluating a surrogate endpoint at three levels, with application to vaccine developmentPeter B Gilbert
Fred Hutchinson Cancer Research Center and Department of Biostatistics, University of Washington, Seattle, WA 98109, USA
Stat Med 27:4758-78. 2008....
Evaluating candidate principal surrogate endpointsPeter B Gilbert
Department of Biostatistics, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109, USA
Biometrics 64:1146-54. 2008..A CEP surface plot provides a way to compare the surrogate value of multiple biomarkers. The approach is illustrated by the problem of assessing an immune response to a vaccine as a surrogate endpoint for infection...
Efficient and robust method for comparing the immunogenicity of candidate vaccines in randomized clinical trialsPeter B Gilbert
Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave North, PO Box 19024, Seattle, WA 98109, USA
Vaccine 27:396-401. 2009..g., readouts from laboratory assays) of vaccine-induced immune responses, and (2) by implementing the proposed semiparametric efficient method in trials where baseline predictors are available...
Some design issues in phase 2B vs phase 3 prevention trials for testing efficacy of products or conceptsPeter B Gilbert
Vaccine Infectious Disease Institute, Fred Hutchinson Cancer Research Center and Department of Biostatistics, University of Washington, Seattle, WA 98109, USA
Stat Med 29:1061-71. 2010..Our objective is to help inform the decision-process for planning an initial efficacy trial design...
Covariability of selected amino acid positions for HIV type 1 subtypes C and BPeter B Gilbert
Department of Biostatistics, University of Washington, and Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
AIDS Res Hum Retroviruses 21:1016-30. 2005..Information on covariability should be better exploited in assessments of HIV-1 diversity and how to surmount it with vaccine design...
Semiparametric estimation of the average causal effect of treatment on an outcome measured after a postrandomization event, with missing outcome dataPeter B Gilbert
Department of Biostatistics, University of Washington, Seattle, WA 98105, USA
Biostatistics 11:34-47. 2010..The new method, which does not require a monotonicity assumption, is evaluated in a simulation study and is applied to data from the first HIV vaccine efficacy trial...
Failure time analysis of HIV vaccine effects on viral load and antiretroviral therapy initiationPeter B Gilbert
Department of Biostatistics, University of Washington and Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109, USA
Biostatistics 6:374-94. 2005..The new method is evaluated in simulations and is applied to the vaccine trial data set...
Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trialsPeter B Gilbert
Vaccine Infectious Disease Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109, USA
J Infect Dis 203:969-75. 2011..Third, we evaluate RV144 for completeness of end point ascertainment and integrity of blinding, necessary tasks for establishing robustly interpretable results...
Genome scanning tests for comparing amino acid sequences between groupsPeter B Gilbert
Fred Hutchinson Cancer Research Center and Department of Biostatistics, University of Washington, Seattle, WA 98109, USA
Biometrics 64:198-207. 2008..The methods are examined in simulations and are applied to two HIV examples. The methods for problem B address the general problem of comparing discrete frequency distributions between groups in a high-dimensional data setting...
Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in SenegalPeter B Gilbert
Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Research Center and Department of Biostatistics, University of Washington, Seattle, WA 98105, U S A
Stat Med 22:573-93. 2003..40 and 3.86. Understanding the mechanisms by which HIV-1 infects more efficiently than HIV-2 may be useful in the development of HIV-1 vaccines. Additionally, the methodology developed here may be useful for analysing other data sets...
What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trialsPeter B Gilbert
Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Research Center, University of Washington, 1100 Fairview Avenue North, Seattle, WA 98109, USA
J Infect Dis 188:179-93. 2003..The assessment suggests that a vaccine demonstrating moderately durable effects to delay therapy and to ameliorate viremia merits consideration for licensure...
Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trialsPeter B Gilbert
Fred Hutchinson Cancer Research Center and Department of Biostatistics, University of Washington, Seattle, Washington 98109, USA
Biometrics 59:531-41. 2003..We show how the procedures can be used for a sensitivity analysis that quantifies how the causal effect of vaccination varies with the presumed magnitude of selection bias...
Two-sample tests for comparing intra-individual genetic sequence diversity between populationsPeter B Gilbert
Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
Biometrics 61:106-17. 2005..The new tests are evaluated theoretically and in a simulation study, and are applied to a dataset of 200 HIV sequences sampled from 21 children...
Nonparametric estimation of the joint distribution of a survival time subject to interval censoring and a continuous mark variableMichael G Hudgens
Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
Biometrics 63:372-80. 2007..Theoretical and empirical evidence are presented indicating the NPMLE and MIDMLE are inconsistent. Conversely, the CMLE is shown to be consistent in general and thus is preferred...
Assessing vaccine effects in repeated low-dose challenge experimentsMichael G Hudgens
Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina 27599, USA
Biometrics 65:1223-32. 2009..Based on the principal stratification framework, we also address evaluation of potential immunological surrogate endpoints for infection...
Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study)Ann Duerr
Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109 1024, USA
J Infect Dis 206:258-66. 2012..97; P=1.0) over all follow-up time. Conclusions: The vaccine-associated risk seen in interim analysis was confirmed but waned with time from vaccination...
Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trialPeter B Gilbert
Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
J Infect Dis 191:666-77. 2005..Although the data cannot definitively discriminate between these 2 explanations, (ii) appears to be more likely...
Sensitivity analyses comparing outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trialsBryan E Shepherd
Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
Biometrics 62:332-42. 2006..We apply our methods to the world's first phase III HIV vaccine trial...
HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccinePeter B Gilbert
Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, USA
J Infect Dis 192:974-83. 2005..The pre-ART viral load and CD4+ lymphocyte count trajectories were also comparable between the groups. Evidently, the vaccine did not affect HIV-1 disease progression...
HIV-1 vaccines and adaptive trial designsLawrence Corey
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Sci Transl Med 3:79ps13. 2011....
Weighted likelihood method for grouped survival data in case-cohort studies with application to HIV vaccine trialsZhiguo Li
Department of Biostatistics, University of Michigan, Ann Arbor, Michigan 48109, USA
Biometrics 64:1247-55. 2008..We apply the method to the HIV vaccine trial data, showing that higher antibody levels are associated with a lower hazard of HIV infection...
A framework for assessing immunological correlates of protection in vaccine trialsLi Qin
Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
J Infect Dis 196:1304-12. 2007..Other real and simulated examples are also discussed...
Power to detect the effects of HIV vaccination in repeated low-dose challenge experimentsMichael G Hudgens
Department of Biostatistics, School of Public Health, University of North Carolina, Chapel Hill, NC 27599, USA
J Infect Dis 200:609-13. 2009..Power generally increases with the maximum number of allowable challenges per animal, the per-exposure risk of infection in control animals, and the proportion of animals susceptible to infection...
Predicting the impact of blocking human immunodeficiency virus type 1 Nef in vivoW David Wick
Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, M2 C200, 1100 Fairview Ave N, Seattle, Washington 98109 1024, USA
J Virol 83:2349-56. 2009..We conclude that inhibiting Nef could make a substantial reduction in disease burden, lengthening the time before the necessity of undertaking combination therapy with other antiretroviral drugs...
Statistical evaluation of HIV vaccines in early clinical trialsZoe Moodie
Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Reasearch Center, 1100 Fairview Ave N, LE 400, PO Box 19024, Seattle, WA 98109 1024, USA
Contemp Clin Trials 27:147-60. 2006..The goal of these early trials is to narrow the number of candidate vaccines to the most promising candidates worthy of further study in efficacy trials...
Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160Deborah Lee
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
J Infect Dis 190:903-7. 2004..4, P =.1, and P =.7, respectively). Persons who acquire HIV-1 infection while enrolled in HIV-1 vaccine trials can be successfully followed after infection, to determine whether vaccines alter the course of HIV-1 infection...
HIV-1 CTL-based vaccine immunogen selection: antigen diversity and cellular response featuresFusheng Li
Statistical Center for HIV Aids Research and Prevention, 1100 Fairview Avenue N, Seattle, WA 98109, USA
Curr HIV Res 5:97-107. 2007..Based on these analyses, several approaches are proposed to enhance the breadth of vaccine responses and, hence, the potential protective efficacy...
Identification of cross-neutralization determinants by GAP analysis: a mutational behavior approachFusheng Li
Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109, USA
Curr HIV Res 5:87-96. 2007..Correlated mutation analysis and structure mapping further refine the cross-neutralization determinants. The usability of this approach is confirmed by analysis of an Influenza H3N2 cross-reactive dataset...
Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccinePeter Gilbert
Vaccine Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
J Infect Dis 202:595-605. 2010..Here we assessed the magnitude and breadth of neutralizing antibody responses in Vax004...
Statistical identifiability and the surrogate endpoint problem, with application to vaccine trialsJulian Wolfson
Department of Biostatistics, University of Washington, Seattle, Washington 98195 7232, USA
Biometrics 66:1153-61. 2010....
Accuracy and precision of estimating intervention efficacy when the timing of observed events differ by treatment armAmalia S Meier
University of Washington, USA
Contemp Clin Trials 26:598-610. 2005..Efforts to re-capture subjects at the end of study for failure assessment are helpful in some contexts, and may be considered in study planning...
MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral loadHolly Janes
Division of Vaccines and Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
PLoS ONE 7:e43396. 2012..We linked the viral sequence data with immune response and acute viral load data to explore mechanisms for and consequences of the observed sieve effect...
Interactive association of proviral load and IFN-gamma-secreting T cell responses in HIV-1C infectionVladimir A Novitsky
Department of Immunology and Infectious Diseases, Harvard School of Public Health, FXB-402, 651 Huntington Avenue, Boston, MA 02115, USA
Virology 349:142-55. 2006....
Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in BotswanaRoger L Shapiro
Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
AIDS 20:1281-8. 2006..This strategy avoids the potential for maternal nevirapine resistance...
A comparison of eight methods for the dual-endpoint evaluation of efficacy in a proof-of-concept HIV vaccine trialDevan V Mehrotra
Merck Research Laboratories, UN A102, 785 Jolly Road, Blue Bell, Pennsylvania 19422, USA
Biometrics 62:893-900. 2006..The adjustment is derived using a selection bias model based on the principal stratification framework of causal inference...
Flexible weighted log-rank tests optimal for detecting early and/or late survival differencesLang Wu
Department of Statistics, University of British Columbia, Vancouver, British Columbia V6T 1Z2, Canada
Biometrics 58:997-1004. 2002..When the main interest is in detecting early and/or late survival differences, these tests may be preferable to the other versatile and weighted log-rank tests that have been studied...
Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rateDonald N Forthal
Division of Infectious Diseases, Department of Medicine, University of California, Irvine, CA 92697, USA
J Immunol 178:6596-603. 2007..However, such activity requires the presence of FcR-bearing effector cells. Our results provide further evidence that ADCVI may play a role in preventing HIV infection...
HIV-1 subtype C in vitro growth and coreceptor utilizationEnoch Sepako
Botswana-Harvard School of Public Health AIDS Initiative Partnership for HIV Research and Education, Private Bag BO320, Bontleng, Gaborone, Botswana, Africa
Virology 347:247-60. 2006..Usage of other coreceptors was rare and apparently insignificant. These results enhance our understanding of HIV-1C biology, with implications for designing and testing therapeutic and prophylactic agents...
Prognostic significance of DCC and p27Kip1 in colorectal cancerJames T Wu
Department of Pathology, University of Illinois, Chicago, Medical Center, Chicago, IL, USA
Appl Immunohistochem Mol Morphol 13:45-54. 2005..87; 95% confidence interval, 0.58-1.29; P=0.49). The present study demonstrated that the expression of neither DCC nor p27Kip1 was predictive in poor survival outcome in patients with stage II or III colorectal cancer...
Research Grants
- Statistical Methods in HIV Vaccine Efficacy TrialsPeter Gilbert; Fiscal Year: 2009..By improving the design and analysis of efficacy and NHP trials for addressing these areas, the project will benefit public health. ..
- Statistical Methods in HIV Vaccine Efficacy TrialsPeter Gilbert; Fiscal Year: 2005..g., immune responses). The fourth aim is to develop accurate simultaneous confidence interval procedures for assessing time-varying effects of vaccination to prevent infection or post-infection outcomes. ..
- Statistical Methods in HIV Vaccine Efficacy TrialsPeter Gilbert; Fiscal Year: 2007..By improving the design and analysis of efficacy and NHP trials for addressing these areas, the project will benefit public health. ..
